Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
NextEra Falls, Seagate Slips, Regeneron Tumbles | Stock Movers
Posted
May 18, 2026
Views
169
Likes
1
Engagement
0.59%
May 18, 2026
169
1
0.59%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
3:44Now PlayingToday's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- NextEra (NEE) agreed to pay about $67 billion in stock for Dominion Energy Inc. in the biggest power acquisition ever, creating a giant utility extending from Florida to the artificial intelligence data centers clustered in Virginia. The scope of the transaction underscores how the spike in AI-driven power demand is pushing the utilities sector to seek ever-greater size and clout. The deal would position NextEra as the dominant utility in a region that’s struggling to meet the surge in electricity consumption. Dominion shares rose 9.4% to $67.56 as trading closed in New York on Monday, while NextEra fell 4.6% to $89.04.
-Seagate (STX) shares fell 6.9% Monday in its worst one-day drop in nearly two months after management comments at a JPMorgan conference sparked investor fears that the company won’t be able to keep up with soaring demand for memory chips. The declines come after a blistering rally in the sector that’s spanned roughly eight weeks, boosted by solid earnings from megacap technology hyperscalers, a slew of deals for the cohort and investor enthusiasm in the risk-on trade as high demand for artificial intelligence infrastructure persists. The SOX gained nearly 60% from the start of April through a May 11 record high.
- Regeneron Pharmaceuticals (REGN) said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. Regeneron’s experimental drug fianlimab couldn’t beat Merck & Co.’s established cancer blockbuster Keytruda in the study, Regeneron said late on Friday. Another head-to-head trial of the Regeneron compound versus Bristol-Myers Squibb Co.’s Opdualag continues. The shares plunged in trading on Monday.
See omnystudio.com/listener () for privacy information.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.
Check out more episodes of Stock Movers
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
#Stocks #Markets #Finance #Investing #Podcast #Bloomberg
NextEra Falls, Seagate Slips, Regeneron Tumbles
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
